Outcome of the Board Meeting
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts less than Nifty Smallcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cohance Lifesciences reported a significant decline in FY26 standalone revenue of ₹2,030.50 Cr (down 19% from ₹2,504.43 Cr in FY25) and consolidated revenue of ₹2,268.55 Cr (down 13% from ₹2,608.50 Cr). Standalone PAT fell to ₹228.71 Cr from ₹491.18 Cr (53% decline), while consolidated PAT attributable to shareholders dropped to ₹179.23 Cr from ₹487.34 Cr (63% decline). The company completed a merger with erstwhile Cohance Lifesciences Limited in May 2025, and prior period figures have been restated to reflect this business combination. Exceptional items of ₹29.47 Cr include ₹16.51 Cr customer settlement, ₹4.86 Cr labour code impact, and ₹2.10 Cr restructuring costs. The statutory auditor (Walker Chandiok & Co LLP) issued an unmodified opinion with an emphasis of matter on the merger restatement.
The sharp revenue and profit decline reflects challenging market conditions. Despite the merger and clean audit, the substantial 53-63% PAT reduction may weigh on investor sentiment. Positive operating cash flows of ₹389.57 Cr (standalone) provide some support.